. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2015 May 1;69(1):1–10. doi: 10.1097/QAI.0000000000000533

Table 4.

Cationic polypeptide levels in cervicovaginal secretions, by hormonal contraceptive use.

	No Hormonal Mean (SD)	DMPA Mean (SD)	Diff.	p	Adj. Diff.^a	Adj. p	Oral Mean (SD)	Diff.	P	Adj. Diff.^a	Adj. p
HNP1–3	2.04 (0.92)	2.38 (0.44)	0.33	0.024^*	0.33	0.036^*	2.23 (0.31)	0.19	0.40	0.17	0.49
LL-37	0.40 (1.06)	0.81 (0.83)	0.40	0.027^*	0.43	0.027^*	0.57 (0.41)	0.17	0.53	0.28	0.35
SLPI	1.86 (0.82)	2.00 (0.56)	0.15	0.27	0.12	0.37	2.27 (0.58)	0.41	0.054	0.36	0.12
Lactoferrin	2.60 (0.80)	3.03 (0.62)	0.42	0.002^**	0.36	0.010^*	2.93 (0.70)	0.33	0.12	0.27	0.26
HBD-2	−0.17 (1.30)	0.01 (1.38)	0.18	0.43	0.27	0.26	0.33 (1.31)	0.49	0.18	0.10	0.81

Abbreviations: DMPA, depot medroxyprogesterone acetate; HNP1–3, human neutrophil peptides 1–3; SLPI, secretory leukocyte protease inhibitor; HBD-2, human beta-defensin 2; SD, standard deviation; Diff, difference, compared to women using no hormonal contraception; Adj, adjusted value

NOTE – Polypeptide concentrations are expressed as log₁₀ ng/ml

Adjusted for presence of PSA in CVS sample, frequency of sex in the past month, and HIV exposure group (i.e., discordant versus concordant negative couple)

p<0.05

^**

p<0.01